Next Generation Process Development and Manufacturing for Cell and Gene Therapies - Improving Efficiencies and Reducing Cost of Goods

When will we have a clone? An industry perspective on the typical CLD timeline

Intensification of Downstream Manufacturing of Recombinant Adeno-Viral Vectors using Continuous Processing

An autonomous Biomanufacturing platform to scale production of autologous iPSC-derived cell therapies